Navigation Links
Upgraded ACCF/ AHA/ SCAI Guidelines Reinforce Benefits of Volcano's Precision Guided Therapy Technologies
Date:11/9/2011

SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guidance therapy tools designed to enhance the treatment of coronary and peripheral vascular disease, supports the elevation of Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR) technologies in the updated clinical guidelines for the management of patients undergoing percutaneous coronary intervention (PCI). The update was issued earlier this week by the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), and Society for Cardiovascular Angiography and Interventions (SCAI).

"The latest guidelines recommend additional use of IVUS and FFR, both of which represent key product lines in Volcano's broad portfolio of precision guided technologies, in patients undergoing PCI," said Scott Huennekens, President and CEO of Volcano Corporation.  "These recommendations confirm the positive role that IVUS and FFR technologies play in the care of PCI patients."

The newly revised guidelines include the use of IVUS for the assessment of intermediate lesions, for guiding stent implantation and for determining the cause of stent thrombosis.  In addition, a new Class IIa recommendation now states that IVUS is reasonable for the assessment of angiographically indeterminate left main coronary artery disease (CAD), which is a new guideline and was not published in prior guidelines.  IVUS and coronary angiography was also included for patients who have heart transplantation including 4-6 weeks post-cardiac transplant and 1 year follow up.  

The guidelines categorize FFR as Class IIa and stated that the technology is reasonable to assess angiographic intermediate coronary lesions (50% to 70% diameter stenosis) and can be useful for guiding revascularization decisions in patients with stable ischemic heart disease.

The guidelines also included that every PCI program should participate in a regional or national PCI registry for the purpose of benchmarking its outcomes against current national norms. Technologies like IVUS and FFR help physicians make more informed clinical decisions and can have a positive impact on the quality scores of a healthcare institution.

About Volcano Corporation

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information—using light and sound as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at www.volcanocorp.com.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.  Any statements in this release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies, growth strategies, timing and achievement of product development milestones, the impact and benefits of market development, product introductions, unexpected new data, safety and technical issues, market conditions, dependence on third parties, and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our  recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

.


'/>"/>
SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
2. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
3. Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction
4. 2011 ACCF/AHA Guidelines Incorporate New Recommendation for Platelet Reactivity Testing
5. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
6. DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
7. New Guidelines: Antibiotic Prophylaxis
8. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
9. Lung Cancer Alliance Commends NCCN on Screening Guidelines
10. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
11. Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  Sanderling Ventures, portfolio company, ... a division of Johnson & Johnson. Torax manufactures and ... treatment of gastro-esophageal reflux disease (GERD). The LINK ... technology and the procedure is currently available in ... Torax Medical was founded by Sanderling Ventures, Mayo ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
(Date:3/27/2017)... March 27, 2017 The global ... USD 16.0 billion by 2025, according to a new ... of chronic diseases is anticipated to be responsible for ... thereby widens the scope for growth during the forecast ... population, which is highly susceptible to chronic diseases, is ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin Harper ... prestigious award honoring the top influencers on RealSelf—the most trusted online destination to ... and clinics. , In 2016, more than 82 million people visited RealSelf to ...
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... awards, now in their 12th year, are among the most prestigious in radiology marketing ... the awards were retooled to recognize achievements in both large budget (over $5,000) and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek Insurance Agencies, ... families and business owners across eastern Michigan, is connecting with the Oxford/Orion FISH ... financial difficulties. , The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, ...
Breaking Medicine News(10 mins):